PFE

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✗

Return

+1.65%

Status

scored

Maintain Underweight rating via the 10/1 tactical override pathway with a calibrated 15-20% trim of the PFE position; set residual stop at $29.00 (daily close basis) and rotate 2/3 of trim proceeds to MRK/JNJ via limit orders -2% to -3% from spot, with 1/3 to cash/T-bills at ~5% carry. Reject the trader's SELL on three grounds: the binding 10/5 reflection caps trim magnitude at 15-20%, the 200 SMA at $25.80 remains intact with price 7.5% above it, and the 1.27x TTM FCF coverage with 330+ consecutive dividend quarters provides genuine carry value. Position around Q3 2026 earnings as the binary forcing catalyst rather than through it.

Outcome

✓

Return

-0.64%

Status

scored

Adopt Underweight rating on PFE with a 15-20% position trim to be executed patiently over 2-4 weeks into $28.50-$29.00 rallies, with a stop at $25.80 (200 SMA, daily close basis); rotate 2/3 of trim proceeds to MRK/JNJ via limit orders -2% to -3% from spot and retain 1/3 in cash/T-bills at ~5% carry for post-Q3 optionality.

Outcome

✗

Return

+1.82%

Status

scored

Pfizer (PFE) is rated UNDERWEIGHT with a recommendation to trim 15-20% of the position to benchmark weight, retaining residual exposure to collect the ~6.3% dividend through the Q2 2026 earnings binary catalyst. The technical setup shows momentum deterioration (RSI collapsed to 43, MACD at -0.13, price testing 50 SMA at $27.44) but the 200 SMA floor at $25.82 remains intact, supporting a measured trim rather than full exit. Hard stop invalidation is set at $25.82 on daily close basis, with re-engagement triggers at $27.96 on >40M volume.

Outcome

–

Return

+0.33%

Status

scored

Underweight rating is maintained with 30-40% trim to below benchmark weight, retaining a residual position for dividend carry (~0.05%/week) while avoiding binary event concentration risk ahead of Q3 2026 earnings. Hard stop set at $25.82 (200 SMA daily close basis); do not add below $27.39 (50 SMA) until confirmed daily close above $28.06 (10 EMA) with RSI recovery above 50. Risk-reward is heavily asymmetric to downside with a 7:1 downside-to-upside ratio and a 5:1 bull-to-bear catalyst requirement ratio.

Outcome

✓

Return

-1.40%

Status

scored

Reduce PFE exposure by trimming 30-40% of the position at $27.70-$27.90 while retaining a residual stake to collect the ~6% dividend carry through the Q3 earnings binary catalyst. Set a structural stop on the residual at $25.80 (200 SMA daily close basis), not the trader's $29.20 stop above entry which is structurally self-defeating for a bearish thesis. Exit fully on dividend cut/freeze announcement, daily close below $25.80 (200 SMA break), or Q3 FCF coverage compression below 1.0x TTM. Rotate 2/3 of trim proceeds to MRK/JNJ and retain 1/3 in cash/T-bills for post-Q3 optionality.

Outcome

✗

Return

-1.14%

Status

scored

Hold PFE with 30-35% trim executed at $28.12, structural stop at $27.00 (just below 50 SMA at $27.26), and hard -3% drift-tolerance trigger at $27.27 requiring mandatory reassessment before Q3 earnings in ~4-5 weeks; rotate 2/3 of trim proceeds to MRK/JNJ via limit orders -2% to -3% from spot and retain 1/3 in cash/T-bills for post-earnings optionality. The rating remains Hold because all three Underweight triggers (impairment-to-dividend linkage, 200 SMA break below $25.79, OCF coverage below 50%) remain unactivated despite a structurally sound bear case, and historical Hold calls have averaged +0.2% to +0.9% alpha versus Underweight bleeding 50-80 bps per event.

Outcome

✗

Return

-1.40%

Status

scored

Hold PFE at neutral weight with $27.19 structural stop; do not tighten stop, upgrade ahead of ESMO, or trim into weakness. Pre-commit contingent action plans for ESMO (~3 weeks) and Q3 2026 earnings (~5 weeks) as binary catalysts; if price drifts -3% from ~$28.52 before either catalyst, mandatory re-evaluation of Hold rating. Rotate 2/3 of any trim proceeds to MRK/JNJ via limit orders -2% to -3% from spot; retain 1/3 in cash/T-bills for post-catalyst optionality.

Outcome

✓

Return

-0.70%

Status

scored

Maintain PFE at Hold rating to collect the ~6% dividend carry while waiting for Q3 2026 earnings (late October) as the binary forcing catalyst. The empirical record shows Hold calls on this exact PFE setup have generated +0.1% to +1.5% alpha versus SPY, while Underweight calls without binding triggers have bled 50-80 bps of alpha. Do not upgrade to Buy at current levels ($28.72) given negative-skew risk/reward (2.7% upside to resistance vs 5.6% downside to support) and lack of breakout confirmation (24.7M volume vs required 40M).

Outcome

✓

Return

0.00%

Status

scored

Hold PFE with a tactical 30% trim executed at $28.50-$28.85 resistance, not into current weakness; stop residual at $26.69 (50 SMA closing basis). The rating remains Hold because none of the three binding Underweight triggers are present: dividend was paid, 200 SMA at $25.57-$25.85 holds with price 7-8% above it, and TTM FCF coverage sits at 1.12-1.28x above the 50% threshold. Rotate 2/3 of trim proceeds to MRK/JNJ and retain 1/3 in cash/Treasuries for post-ESMO and post-Q3 2026 earnings optionality.

Outcome

✓

Return

+0.17%

Status

scored

Maintain PFE at Hold, collecting the 6.1% dividend carry on existing positions while deferring new capital deployment until price pulls back into the $27.50-$28.10 zone. Do not chase the current $28.67 level with MACD histogram turning negative and MACD divergence on light volume. Entry triggers include pullback to entry zone and confirmation signals; stop at $26.85 closing basis.

Outcome

✓

Return

+0.92%

Status

scored

Maintain PFE at Hold rating with a calibrated 30% trim rather than full exit, as all three Underweight triggers (dividend impairment linkage, 200 SMA break, FCF coverage below 50%) remain absent despite deteriorating technicals; execute the trim at technical resistance zones ($28.50-$28.85 and $28.95-$29.20), not into current weakness. Rotate 2/3 of proceeds to MRK/JNJ via limit orders 2-3% below spot and retain 1/3 in cash/Treasuries for Q3 2026 earnings optionality, with stop loss at $26.69 and mandatory re-engagement triggers defined for both directions.

Outcome

✓

Return

+0.82%

Status

scored

Maintain PFE at moderate 2-3% portfolio sizing with an opportunistic ~25% trim via limit orders at $28.50-$29.00 resistance — explicitly not into current ~$28.18 weakness — while rotating 2/3 of proceeds to MRK/JNJ and retaining 1/3 in cash/Treasuries; stop loss sits at $26.70 (50 SMA) with escalation to full Sell on any daily close below $25.50 (200 SMA break). The HOLD rating is binding because all three Underweight triggers are absent: dividend remains paid, 200 SMA holds at $25.57-$25.85, and TTM FCF coverage of 1.27-1.28x is well above the 50% compression threshold.

Outcome

✓

Return

+0.90%

Status

scored

Maintain Hold rating on PFE as the 3 Underweight triggers (dividend cut, 200 SMA breakdown below $25.50-$25.85, FCF coverage compression below 50%) are absent; position sized to absorb 15-20% adverse move with stops at $26.69 (50 SMA) and $25.50 (200 SMA hard inversion); pre-commit add trigger at $27.46-$27.50 retest with stop $27.12 and exit trigger below $26.69; Q3 2026 earnings (late October) is the binary forcing catalyst to re-evaluate the position.

Outcome

✗

Return

+0.68%

Status

scored

Trim 30-40% of PFE via limit orders at $28.30-$28.50 resistance (not current $27.74 weakness), stop residual at $26.50, escalate to full Sell if price closes below $25.50 (200 SMA), and rotate 2/3 of proceeds to MRK/JNJ while holding 1/3 in cash/T-bills for post-Q3 2026 earnings optionality.

Outcome

✓

Return

+0.29%

Status

scored

The portfolio manager rates PFE HOLD while executing a ~25% trim due to deteriorating technicals (below 10 EMA, MACD bearish cross, RSI at ~52) ahead of a binary Q3 2026 earnings catalyst in late October. The trim captures structural concerns (6.22% yield signaling dividend risk, Seagen impairment, patent cliff) without triggering a rating downgrade, since all three binding Underweight triggers are absent: no dividend cut, 200 SMA intact at $25.57-$25.85, and FCF coverage strong at 1.28x.

Outcome

✓

Return

+0.07%

Status

scored

Maintain Hold on PFE despite tactical trim recommendation; technical deterioration does not meet the binding Underweight triggers (dividend paid, 200 SMA at $25.57-$25.85 intact, TTM FCF coverage at 1.27-1.28x above 50% threshold). Execute a ~25% trim across $27.60-$27.80 (first tranche ~12-13%) and $28.30-$28.50 bounce (second tranche ~12-13%), rotate 2/3 of proceeds to MRK/JNJ, retain 1/3 in cash/short-duration Treasuries, and reassess after Q3 2026 earnings in late October.

Outcome

✓

Return

+0.66%

Status

scored

Maintain PFE at HOLD despite deteriorating fundamentals because the 9/11 Underweight threshold is not met—no confirmed impairment-to-dividend linkage, 200 SMA break, or OCF coverage compression below 50%. Execute phased trim of 15-25% via laddered limit sells at $27.70/$27.90/$28.20, with hard stop at $25.85; reassess at Q3 2026 earnings (late October) as the binary forcing catalyst.

Outcome

✓

Return

-0.33%

Status

scored

Maintain PFE at 2-3% portfolio cap with the structural floor at $25.85 as the invalidation line; trim 10-20% into any rally toward $28.50-$29.00 and execute a conditional 10% reduction only on a confirmed close below $27.17 with volume exceeding 50M shares; maintain no-adds discipline below $27.55 unless Q3 2026 FCF exceeds $3.0-3.5B (100-140% dividend coverage), which is the binary catalyst arriving in late October.

Outcome

✓

Return

-0.61%

Status

scored

Maintain PFE at moderate sizing (2-3% portfolio cap) as the convergent Hold is correct—this is a patient posture, not fearful indecision. The 6.2% dividend yield and 9.6x forward P/E provide yield-driven support, but tactical addition requires confirmed reversal off $26.00-$26.50 with MACD re-flip positive or post-Q3'26 earnings confirmation; Q3'26 earnings (mid-October) is the binary forcing catalyst for thesis re-evaluation.

Outcome

–

Return

0.00%

Status

scored

Reduce PFE exposure by 25-33% via staged exits in the $28.00-$28.50 zone, holding residual ~two-thirds position with stop at $25.50 closing basis; the trim opportunity at $29+ has passed but $28.00-$28.50 remains executable on relief bounces. Redirect 50% of trimmed capital to higher-quality defensives (JNJ/ABBV) and keep 50% in cash/short-duration Treasuries for post-Q3 re-engagement optionality. Hard invalidation at $24.00 close escalates to Sell; full reassessment at Q3 2026 earnings (late October).

Outcome

✓

Return

+0.25%

Status

scored

Analysts maintain HOLD on PFE at 2-3% portfolio sizing, rejecting both aggressive addition at $27.65 and further trimming. The 9.5x forward P/E versus 13-15x peer multiples, $6B net debt reduction since 2023, and 6.2% dividend yield with 1.27x FCF coverage provide defensive support, but failed technical breakout at $29.21, negative MACD histogram, and price below the 10-EMA at $28.07 argue against pre-earnings accumulation. Q3 2026 earnings (late October) is the binary forcing event that will determine whether H1 FCF deterioration is a working-capital artifact or structural break.

Outcome

✓

Return

-0.47%

Status

scored

Maintain PFE at HOLD despite a fresh MACD bearish cross and three-indicator technical deterioration, because the 6.19% dividend carry compresses realized downside capture and prior Underweight calls underperformed Hold calls by 1.3-3.0 percentage points. The 9/8 binding reflection explicitly handled this setup at virtually the same price ($27.79 vs $27.78) with identical 200 SMA support, dividend, and FCF coverage; the trim opportunity has been partially realized through price action. Working stop at $25.49 with tactical add levels at $25.90-$26.00 and $25.20-$25.49; await Q3 2026 earnings (late October) as the binary forcing catalyst.

Outcome

✓

Return

-0.04%

Status

scored

Maintain HOLD at moderate sizing (2-3% portfolio cap) on PFE at $27.79, neither adding nor trimming at current levels. The decision reflects convergent analyst agreement that valuation (9.6x forward P/E vs 15-18x sector, 6% dividend yield with 1.27x FCF coverage) supports holding, but technical deterioration and execution risk (Q2 FCF collapse to $302M, $4.3B impairment, ROE 5.0% below cost of capital) argue against adding. Working stop set at $25.47 (200 SMA) on closing basis; Q3 2026 earnings (late October) is the binary forcing catalyst that will resolve the bifurcation between bull valuation and bear execution.

Outcome

✓

Return

-2.32%

Status

scored

Trim PFE by 30-35% from current weight to roughly two-thirds of prior allocation due to bearish technical setup (10% extension above 50 SMA, RSI rolled from 77 to 63, MACD histogram negative, 52-week high rejection at $29.21) and deteriorating FCF coverage (H1 at 50.7% vs 93% full-year 2025). Maintain residual with working stop at $25.82; reassess at Q3 2026 earnings (late October) as binary forcing catalyst.

Outcome

–

Return

-1.25%

Status

scored

Pfizer is rated Underweight with a recommendation to trim existing exposure by 25-33% (closer to 30%) at $28.81, citing extension/overbought signals (RSI at 68.85, +12% above 50 SMA, 52-week high proximity) and H1 2026 FCF coverage of only 0.51× of dividend. The working stop is set at $27.00 closing basis with hard invalidation at $25.20, while new capital should wait for re-entry in the $26.50-$27.50 zone ahead of Q3 2026 earnings as the binary catalyst.

Outcome

✓

Return

-0.72%

Status

scored

Hold PFE at current exposure without preemptive trim, citing the binding 9/1 PFE lesson which requires confirmed distribution or momentum failure before trimming — neither present despite RSI 72.4 and 52-week highs. The constructive technical structure (golden cross confirmed, MACD positive, bullish MA stacking) combined with 6% dividend, 1.27x TTM FCF coverage, and 0.28 beta in an 89% no-cut macro regime supports maintaining positions. For new capital, wait for the $25.50-$27.00 entry zone rather than initiating at $29.02.

Outcome

✗

Return

+1.65%

Status

scored

Analysts unanimously recommend HOLD on PFE at current exposure with no preemptive trim. The 8/31 binding lesson explicitly requires "confirmed distribution or momentum failure" to justify a trim — neither is present given RSI 69.27 without negative divergence, MACD still positive at +0.05, and no volume climax. Working stop tightened to $27.00 (below 20 SMA/middle Bollinger), with hard invalidation at $25.36 (200 SMA); Q3 2026 earnings in late October is the binary forcing event to validate the $2.90 forward EPS thesis and resolve the 9.86x multiple debate.

Outcome

✓

Return

+0.32%

Status

scored

Pfizer receives a HOLD rating with convergent analyst agreement despite negative expected value (-1.84%) at current price of $28.46, as no forcing catalyst exists for Underweight. Existing holders should trim 20-30% of positions into strength while retaining a 60-70% core for dividend carry and structural rerating optionality, with new investors advised to await better entry at $27.12-$27.50 or $25.35-$25.50 zones.

Outcome

✗

Return

+1.79%

Status

scored

Pfizer is downgraded to Underweight with a 30% position trim (at the upper end of the 25-33% band) following a third $4.33B impairment charge in nine months and a 93% single-quarter FCF collapse that pushed dividend coverage to just 12%. The residual position is capped at 1.0-1.5% of book with a tightened stop at $25.50, while re-engagement is reserved for $24.00 or below, or a volume-confirmed breakout above $28.75 with RSI reset to 55-60.

Outcome

–

Return

-0.21%

Status

scored

Pfizer should be trimmed from 2-3% to 1.0-1.5% book weight over 3-5 sessions, targeting strength toward the $28.57-$28.75 resistance cluster, while preserving the residual position to maintain dividend carry and breakout optionality. The stop on residual positions should be tightened to $25.40-$25.50 (closing basis), with re-engagement triggers including a confirmed breakout above $28.75 on volume >50M with RSI 55-60, or a pullback into $26.50-$27.00 with MACD re-expansion, or a clean Q3 2026 print with FCF >$2.0B and dividend reaffirmed. Full liquidation is explicitly avoided per 8/20/8/21 lessons, requiring either a confirmed dividend cut signal or 200 SMA breakdown as precondition for complete exit.

Outcome

✓

Return

-0.99%

Status

scored

Maintain PFE at Hold with the 3-4% book cap unchanged as RSI 69.65, upper Bollinger at $29.09, and decelerating MACD histogram cluster as resistance preventing addition at $28.30. Stage limit-buy triggers at $26.80-$27.70 for half-size entries with full addition only on volume-confirmed breakout above $29.09, using $25.00 as hard stop and Q3 2026 print (October) as the structural re-evaluation forcing event.

Outcome

✓

Return

-0.95%

Status

scored

Pfizer should be trimmed to 50-55% of model weight in the $28.50-$28.93 zone to harvest the overbought premium, given RSI at 73.95 and bearish MACD divergence at the upper Bollinger band, while retaining a residual position rather than full liquidation due to intact multi-MA uptrend, 1.28x FCF coverage, and 6.15% yield supporting income anchor. Use the 10 EMA at $27.57 as the primary trend-break stop and the $25.22 50 SMA cluster as the structural-break exit; re-engage on confirmed breakout above $28.93 with volume >50M and RSI reset, or on pullback into $26.50-$27.00 with MACD re-expansion.

Outcome

✗

Return

+2.15%

Status

scored

Maintain PFE at 3-4% book cap while collecting the 6.13% dividend yield, as resistance at $28.00-$28.65 (RSI 70.14, double top rejection, upper Bollinger Band) makes near-term risk/reward unfavorable with 2.5% upside versus 7% downside to the $25.50-$26.50 SMA cluster. New capital deploys only via a three-tier framework: Tier 1 at $25.50-$26.50, Tier 2 at $27.35 with MACD confirmation, or Tier 3 on confirmed breakout above $28.65 with volume exceeding 30M shares. Re-evaluate directionally at Q3 2026 earnings (October) when FCF coverage and patent cliff concerns will be resolved.

Outcome

✓

Return

-0.36%

Status

scored

Trim PFE by approximately 25% into the $28.00–$28.30 zone to harvest momentum from the 20% two-month rally, while retaining a benchmark-weight residual for the 6.19% dividend carry. Use $26.30 as the hard invalidation stop and reassess after Q3 2026 earnings in October; new investors should not initiate at current levels but can add on pullbacks to $26.80–$27.20 with stabilization.

Outcome

–

Return

+1.01%

Status

scored

Pfizer warrants an Underweight rating with a target of $25.50 over 30-60 days, recommending a 40-50% position reduction in the $27.50-$28.00 range while retaining a 20-25% residual as optionality with a $26.80 protective stop. The thesis is supported by Q2 2026 FCF collapsing 93% to $0.30B (annualizing to just 12% dividend coverage), two EPS misses, $8.8B impairments, and negative tangible book value of -$33.3B, though the bull case for retention includes a 9.6x forward P/E, 6.3% yield, and TTM FCF of $12.5B covering the dividend by 1.28x.

Outcome

✓

Return

-1.59%

Status

scored

Pfizer (PFE) is rated Underweight with a recommendation to trim 40-50% of positions at current levels ($28.00-$28.50) given overbought extremes (RSI 77.36, price above upper Bollinger Band at $28.09) following a +21% rally over 39 sessions; retain 50-70% residual with tiered re-engagement triggers at $24.00-$25.00 or confirmation above $29. Re-evaluation forced by Q3 2026 earnings in October.

Outcome

✗

Return

+3.63%

Status

scored

Maintain PFE at 3-4% book cap as Hold is the correct action at $27.00 near the $27.53 upper Bollinger resistance where near-term risk/reward is unfavorable (2.5% upside vs 7% downside). The 6.4% yield carries the position while awaiting Q3 2026 earnings (mid-October) as the binary catalyst to upgrade to Overweight (clean print, operating income >$4.5B, no new impairments) or downgrade to Underweight ($3B+ impairment, dividend cut, or sustained break below $24.50). Hard stop at $23.21 preserves capital given negative tangible book value, $69B goodwill tail risk, and $62.2B net debt.

Outcome

✗

Return

+1.41%

Status

scored

Maintain Pfizer at current weight with a Hold rating. Do not add at $26.87 as the stock is at the 70th percentile of its 52-week range with overhead resistance at $27.05 double-failing on declining volume (23.95M vs 40-60M prior). Q3 2026 earnings in October is the structural forcing event for re-evaluation, with upgrade triggers at Q3 FCF > $2.5B and downgrade triggers at Q3 FCF < $1B or dividend language softening.

Outcome

✗

Return

+0.30%

Status

scored

Pfizer warrants an Underweight rating with a targeted 40-50% trim from conviction sizing down to 1.5-2.0% book exposure, executed into the $27.20–$27.39 resistance band rather than chasing spot near $26.79. The Q2 FCF collapse (12% coverage ratio), resistance-bound entry levels, Seagen-era write-down pattern, and 9.25x forward P/E built on optimistic EPS consensus outweigh the bull case, but the 6.42% yield, 0.28 beta, CEO-led insider buying cluster, and confirmed breakout from the multi-month base justify maintaining a residual position rather than a full exit. Hard long-thesis invalidation sits at $25.40; re-engagement trigger at confirmed close above $28.75 on expanding volume.

Outcome

✓

Return

-0.04%

Status

scored

Maintain PFE position unchanged at HOLD, sizing to the 6.46% income contribution rather than active upside capture. Do NOT add at current levels ($26.80) due to unfavorable risk/reward at the 70th percentile of the 52-week range with resistance at $27.22; instead, execute a three-tier confirmation-based scale-in framework (tactical add at $26.17, value-zone add at $25.40, or breakout trigger above $27.22) with hard stop at $24.50 weekly close.

Outcome

✗

Return

+1.86%

Status

scored

Maintain PFE at current weight with a Hold rating as the price at $26.31 is not an attractive entry point—the aggressive analyst wants to add only on dips while the conservative analyst wants confirmation. Key technical levels are $25.20–$25.40 for adding and $27.00–$27.20 for trimming, with a hard stop at $24.80. The Q3 2026 earnings print in October is the structural forcing event for re-evaluation.

Outcome

✓

Return

-1.16%

Status

scored

Execute a 40-45% trim of PFE at $26.62, retaining a residual position with a hard stop at $25.00. Staged re-entry is targeted between $24-25 on structural confirmation (close above 10 EMA on rising volume plus MACD bullish crossover), sized at one-third of the trimmed amount per tranche. Reassess at Q3 2026 earnings for either FCF recovery or formal dividend reaffirmation language before considering larger repositioning.

Outcome

✓

Return

-1.59%

Status

scored

Trim PFE exposure by approximately 50% at the current $27 level to capture momentum premium, establishing a collar hedge on the residual position (sell 28-29 call, buy 24 put) to monetize elevated implied volatility while capping dividend-cut tail risk. Re-entry into a meaningful position requires price in the $24.50-$25.50 zone with RSI reset to 55-60, hard stop below the 50 SMA at $24.77, and is contingent on Q3 FCF and dividend commentary; the structural re-evaluation horizon is 6-12 months.

Outcome

✓

Return

+1.08%

Status

scored

PFE is rated Buy with a staged entry strategy due to its stacked catalyst calendar (Starboard activism, berobenatide readout, Seagen ramp, cost program), 6.56% dividend yield, and 9.3x forward P/E versus 11-13x normalized fair value. A breakout entry is recommended at $27.00-$27.20, with a pullback contingency at $25.00-$25.50, stop at $25.50, and $32 price target over 6-12 months.